Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT02263430
Other study ID # PINS-007
Secondary ID
Status Not yet recruiting
Phase N/A
First received September 28, 2014
Last updated October 13, 2016
Start date December 2016
Est. completion date December 2018

Study information

Verified date August 2016
Source Beijing Pins Medical Co., Ltd
Contact Jia Fumin, PhD
Phone 010-59361265
Email pins_medical@163.com
Is FDA regulated No
Health authority China: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

Deep Brain Stimulation (DBS) of the Globus pallidus internus(GPi) is useful in the treatment of different forms of chorea, including Huntington's disease (HD).


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 8
Est. completion date December 2018
Est. primary completion date December 2018
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

1. Subject clinically symptomatic and genetically confirmed Huntington Disease (number of CAG repeats>= 36)

2. Moderate stage of the disease (UHDRS motor>= 30)

3. Predominant movement disorder

4. Compliance of the patient, stable cognition during a 6 months phase prior to inclusion (Mattis Dementia Rating Scales(MDS)>/= 120)

5. Signed informed consent.

Exclusion Criteria:

1. Patients with hearing impairment;

2. Failures of important organs and in severe conditions;

3. Be reluctant or disabled to receive neuropsychological assessments;

4. Participate in other clinical trial;

5. Has a life expectancy of < 1 year.

6. The investigator and/or enrollment review committee, would preclude participation in the study.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Device:
Deep Brain Stimulation


Locations

Country Name City State
n/a

Sponsors (2)

Lead Sponsor Collaborator
Beijing Pins Medical Co., Ltd Beijing Tiantan Hospital

Outcome

Type Measure Description Time frame Safety issue
Primary Unified Huntington's Disease Rating Scale(UHDRS) 12 month Yes
See also
  Status Clinical Trial Phase
Recruiting NCT04120493 - Safety and Proof-of-Concept (POC) Study With AMT-130 in Adults With Early Manifest Huntington's Disease Phase 1/Phase 2
Completed NCT02956148 - Follow-up Measurement of Brain PDE10A Enzyme Levels in Huntington´s Disease Gene Expansion Carriers Early Phase 1
Terminated NCT02494778 - A Study Evaluating if Pridopidine is Safe, Efficacious, and Tolerable in Patients With Huntington's Disease Phase 2
Completed NCT02216474 - Brain Stimulation in Movement Disorders N/A
Completed NCT02208934 - Study To Assess the Safety and Tolerability of Single Ascending Oral Doses of PBF-999 in Healthy Young Male Volunteers Phase 1
Completed NCT02197130 - Randomized, Placebo Controlled Study Of The Efficacy And Safety Of PF-02545920 In Subjects With Huntington's Disease Phase 2
Completed NCT01806896 - Study Evaluating The Safety, Tolerability And Brain Function Of 2 Doses Of PF-0254920 In Subjects With Early Huntington's Disease Phase 2
Completed NCT01502046 - Neuroprotection by Cannabinoids in Huntington's Disease Phase 2
Terminated NCT00712426 - Creatine Safety, Tolerability, & Efficacy in Huntington's Disease (CREST-E) Phase 3
Completed NCT00670709 - Examination of Quantitative Electroencephalographic (QEEG) Biomarkers in Huntington's Disease
Completed NCT00029874 - Minocycline in Patients With Huntington's Disease Phase 1/Phase 2
Terminated NCT02231580 - Study Exploring Safety, Pharmacokinetic and Pharmacodynamic of BN82451 in Male Huntington's Disease Patients Phase 2
Completed NCT02215616 - A Clinical Study in Participants With Huntington's Disease (HD) to Assess Efficacy and Safety of Three Oral Doses of Laquinimod Phase 2
Not yet recruiting NCT02551705 - Functional Imaging of Social Cognition in Premanifest Huntington's Disease N/A
Active, not recruiting NCT02101957 - Multicentric Trial of the Treatment of Huntington's Disease by Cysteamine (RP103) Phase 2/Phase 3
Completed NCT00975481 - A Study To Evaluate The Abuse Potential Of Single Oral Doses Of Dimebon (Latrepirdine) In Healthy Recreational Polydrug Users Phase 1
Completed NCT01521832 - Escalating Dose Study in Healthy Volunteers With SEN0014196 Phase 1
Completed NCT00990613 - A Study Evaluating The Absorption Of Dimebon Into The Body From A Dimebon Solution Applied To The Skin Phase 1
Completed NCT00387270 - Safety Study of the Novel Drug Dimebon to Treat Patients With Huntington's Disease Phase 1/Phase 2
Completed NCT00095355 - Effects of Lithium and Divalproex`on Brain-Derived Neurotrophic Factor in Huntington's Disease Phase 2